NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.32 -0.06 (-0.08%) GOLD FUTURES
2,324.00 -0.20 (-0.01%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
49,887.66 -670.55 (-1.33%)
Edgewise Therapeutics, Inc. (EWTX)
After hours:
| Previous close | 20.34 |
| Open | 20.37 |
| Bid | 21.20 x 600 |
| Ask | 21.28 x 300 |
| Day's range | 20.02 - 21.57 |
| 52-week range | 5.12 - 21.57 |
| Volume | |
| Avg. volume | 735,606 |
| Market cap | 1.983B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.57 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 31.17 |
Business WireEdgewise Therapeutics Appoints Arlene Morris to its Board of Directors
BOULDER, Colo., May 07, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles.
Business WireEdgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
BOULDER, Colo., May 06, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCM trial of EDG-7500. EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction. The Phase 2 trial will assess the safety, tolerabili
Business WireEdgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
BOULDER, Colo., April 23, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten for the treatment of Becker muscular dystrophy (Becker) and for the treatment of Duchenne muscular dystrophy (Duchenne). Sevasemten is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage. Sevasemten is curr
